Read-Gene S.A. (WSE:RDG)

Market Cap	71.21M +21.5%
Revenue (ttm)	15.19M +19.9%
Net Income	-887.46K
EPS	-0.08
Shares Out	11.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84
Average Volume	637
Open	5.98
Previous Close	5.98
Day's Range	5.76 - 6.04
52-Week Range	3.80 - 6.90
Beta	0.54
RSI	57.63
Earnings Date	Feb 10, 2026

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic oncology consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. It ...

• Industry: Biotechnology & Medical Research
• Sector: Healthcare
• Founded: 2005
• Employees: 20
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RDG

Financial Performance

In 2024, Read-Gene's revenue was 13.23 million, an increase of 30.38% compared to the previous year's 10.15 million. Losses were -1.11 million, -17.49% less than in 2023.